Immune function analysis after interferon treatment in post-surgery patients with localized clear cell renal cell carcinoma
10.3724/SP.J.1008.2012.001028
- Author:
Wei CHEN
1
Author Information
1. Department of Urology, Changhai Hospital, Second Military Medical University
- Publication Type:Journal Article
- Keywords:
Immune function;
Immunotherapy;
Interferon alfa-2b;
Kidney neoplasms
- From:
Academic Journal of Second Military Medical University
2012;33(9):1028-1032
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the influence of interferon adjuvant therapy on immune parameters in postoperative patients with localized clear cell renal cell carcinoma (LCCRCC) and explore the related clinical significance. Methods Thirty-five patients with LCCRCC were treated with interferon α-2b hypodermic injection after surgery (6 MIU/time, three times per week for three months). Immune parameters, including CD4+,CD8+,CD4+/CD8+,CD16+56+,CD19+, IL-2, IL-6, IL-10, IL-8, and TNF-α, were determined before and at the 1st, 2nd, 4th, 8th, and 16th week after therapy. And the results were compared before and after therapy. ResultsThree months after therapy, the levels of CD4+, CD8+ and CD4+/CD8+ were not significantly different from those before therapy. The of CD16+56+ was increased significantly during the first two weeks' of treatment (P<0.05) and was significantly declined at the end of therapy (P<0.01). Compared with that before therapy, CD19+ levels were decreased in the 1st, 2nd and 4th week after treatment (all P<0.01), and was significantly increased at the 16th week (P<0.01). The level of IL-8 was significantly decreased at the 4th week after therapy (P<0.05) and TNF-α level was increased at the 8th week after therapy (P<0.01); the levels of other humoral immune parameters were not significantly different from those before therapy. Conclusion Treatment with interferon α-2b hypodermic injection (6 MIU/time, three times/week for three months) has a limited effect on promoting the immunity of patients with LCCRCC, and its influence on the long-term survival patients also needs further study.
